vs
Side-by-side financial comparison of AMERISAFE INC (AMSF) and STEM, INC. (STEM). Click either name above to swap in a different company.
AMERISAFE INC is the larger business by last-quarter revenue ($80.1M vs $47.1M, roughly 1.7× STEM, INC.). AMERISAFE INC runs the higher net margin — 10.2% vs -33.9%, a 44.1% gap on every dollar of revenue. On growth, AMERISAFE INC posted the faster year-over-year revenue change (10.3% vs -15.6%). Over the past eight quarters, STEM, INC.'s revenue compounded faster (36.1% CAGR vs 2.8%).
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
AMSF vs STEM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $80.1M | $47.1M |
| Net Profit | $8.1M | $-16.0M |
| Gross Margin | — | 48.9% |
| Operating Margin | — | -17.7% |
| Net Margin | 10.2% | -33.9% |
| Revenue YoY | 10.3% | -15.6% |
| Net Profit YoY | -9.0% | 68.8% |
| EPS (diluted) | $0.43 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $80.1M | — | ||
| Q4 25 | $81.6M | $47.1M | ||
| Q3 25 | $82.0M | $38.2M | ||
| Q2 25 | $81.1M | $38.4M | ||
| Q1 25 | $72.6M | $32.5M | ||
| Q4 24 | $74.0M | $55.8M | ||
| Q3 24 | $78.7M | $29.3M | ||
| Q2 24 | $75.8M | $34.0M |
| Q1 26 | $8.1M | — | ||
| Q4 25 | $10.4M | $-16.0M | ||
| Q3 25 | $13.8M | $-23.8M | ||
| Q2 25 | $14.0M | $202.5M | ||
| Q1 25 | $8.9M | $-25.0M | ||
| Q4 24 | $13.2M | $-51.1M | ||
| Q3 24 | $14.3M | $-148.3M | ||
| Q2 24 | $11.0M | $-582.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 48.9% | ||
| Q3 25 | — | 35.5% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 32.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | — | 21.2% | ||
| Q2 24 | — | 27.6% |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | -17.7% | ||
| Q3 25 | 21.3% | -33.6% | ||
| Q2 25 | 21.5% | -34.8% | ||
| Q1 25 | 15.5% | -65.0% | ||
| Q4 24 | 22.7% | -84.4% | ||
| Q3 24 | 22.6% | -493.2% | ||
| Q2 24 | 18.1% | -1705.5% |
| Q1 26 | 10.2% | — | ||
| Q4 25 | 12.8% | -33.9% | ||
| Q3 25 | 16.9% | -62.2% | ||
| Q2 25 | 17.2% | 527.8% | ||
| Q1 25 | 12.3% | -76.9% | ||
| Q4 24 | 17.8% | -91.6% | ||
| Q3 24 | 18.2% | -506.3% | ||
| Q2 24 | 14.5% | -1712.6% |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.55 | $-4.40 | ||
| Q3 25 | $0.72 | $-2.84 | ||
| Q2 25 | $0.73 | $-1.79 | ||
| Q1 25 | $0.47 | $-0.15 | ||
| Q4 24 | $0.69 | $-15.29 | ||
| Q3 24 | $0.75 | $-18.24 | ||
| Q2 24 | $0.57 | $-71.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.2M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $246.6M | $-249.4M |
| Total Assets | — | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.2M | — | ||
| Q4 25 | $61.9M | $48.9M | ||
| Q3 25 | $54.7M | $43.1M | ||
| Q2 25 | $48.5M | $40.8M | ||
| Q1 25 | $44.8M | $58.6M | ||
| Q4 24 | $44.1M | $56.3M | ||
| Q3 24 | $63.7M | $75.4M | ||
| Q2 24 | $30.6M | $89.6M |
| Q1 26 | $246.6M | — | ||
| Q4 25 | $251.6M | $-249.4M | ||
| Q3 25 | $274.8M | $-235.7M | ||
| Q2 25 | $265.6M | $-214.1M | ||
| Q1 25 | $260.8M | $-417.5M | ||
| Q4 24 | $257.3M | $-398.4M | ||
| Q3 24 | $314.4M | $-344.1M | ||
| Q2 24 | $301.0M | $-203.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $308.9M | ||
| Q3 25 | $1.2B | $362.6M | ||
| Q2 25 | $1.2B | $379.2M | ||
| Q1 25 | $1.2B | $405.1M | ||
| Q4 24 | $1.2B | $437.4M | ||
| Q3 24 | $1.3B | $537.8M | ||
| Q2 24 | $1.2B | $691.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $8.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.1M | $8.2M | ||
| Q3 25 | $10.7M | $11.4M | ||
| Q2 25 | $-8.4M | $-21.3M | ||
| Q1 25 | $-1.8M | $8.5M | ||
| Q4 24 | $24.2M | $-14.7M | ||
| Q3 24 | $8.4M | $-9.4M | ||
| Q2 24 | $-2.6M | $-11.9M |
| Q1 26 | — | — | ||
| Q4 25 | $8.9M | — | ||
| Q3 25 | $9.8M | — | ||
| Q2 25 | $-9.5M | — | ||
| Q1 25 | $-1.8M | — | ||
| Q4 24 | $23.4M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $-2.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | -11.7% | — | ||
| Q1 25 | -2.5% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | -3.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.06× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | -0.61× | -0.11× | ||
| Q1 25 | -0.20× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 0.59× | — | ||
| Q2 24 | -0.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
